Evicenter
Vyndamax (tafamidis) in Transthyretin amyloid cardiomyopathy
Manufacturer
Pfizer Inc
Questions
71
Last updated

All questions

Pharmacology: Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy

7 questions · 2 sources

Mechanism

How does Vyndamax work (mechanism of action)?

Vyndamax: how much TTR stabilization does tafamidis achieve at the approved dose?

Note: The ≥96% figure is an in vitro measurement in plasma at dose-relevant tafamidis concentrations (the study evaluated 1 to 30 μM; the page gives a mean peak plasma concentration of about 28 μM for tafamidis meglumine 80 mg once daily, VYNDAQEL). The 92% figure is derived from a model-based analysis, as the fourth passage states.

Pharmacokinetics

How is Vyndamax metabolized and eliminated?

What is the half-life of Vyndamax?

How quickly is Vyndamax absorbed?

How much of Vyndamax is bound to plasma proteins?

Components

What are the inactive ingredients in Vyndamax?